These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29149426)

  • 1. Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma.
    Altan B; Kaira K; Watanabe A; Kubo N; Bao P; Dolgormaa G; Bilguun EO; Araki K; Kanai Y; Yokobori T; Oyama T; Nishiyama M; Kuwano H; Shirabe K
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):141-153. PubMed ID: 29149426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas.
    Yanagisawa N; Ichinoe M; Mikami T; Nakada N; Hana K; Koizumi W; Endou H; Okayasu I
    J Clin Pathol; 2012 Nov; 65(11):1019-23. PubMed ID: 22813728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer.
    Kaira K; Sunose Y; Arakawa K; Ogawa T; Sunaga N; Shimizu K; Tominaga H; Oriuchi N; Itoh H; Nagamori S; Kanai Y; Segawa A; Furuya M; Mori M; Oyama T; Takeyoshi I
    Br J Cancer; 2012 Aug; 107(4):632-8. PubMed ID: 22805328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
    Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer.
    Kaira K; Sunose Y; Ohshima Y; Ishioka NS; Arakawa K; Ogawa T; Sunaga N; Shimizu K; Tominaga H; Oriuchi N; Itoh H; Nagamori S; Kanai Y; Yamaguchi A; Segawa A; Ide M; Mori M; Oyama T; Takeyoshi I
    BMC Cancer; 2013 Oct; 13():482. PubMed ID: 24131658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients.
    Lee SH; Kim H; Hwang JH; Lee HS; Cho JY; Yoon YS; Han HS
    Pathol Int; 2012 Mar; 62(3):167-75. PubMed ID: 22360504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence.
    Kaira K; Takahashi T; Murakami H; Shukuya T; Kenmotsu H; Naito T; Oriuchi N; Kanai Y; Endo M; Kondo H; Nakajima T; Yamamoto N
    Anticancer Res; 2011 Nov; 31(11):3775-82. PubMed ID: 22110199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression and clinical significance of Tspan 1 and Integrin α6 in human pancreatic ductal adenocarcinoma].
    Shi G; Dong M; Sheng W; Zhou J; Yu D; Sun W
    Zhonghua Wai Ke Za Zhi; 2014 Oct; 52(10):781-6. PubMed ID: 25573220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of ATF4 mediates the cellular adaptation to pharmacologic inhibition of amino acid transporter LAT1 in pancreatic ductal adenocarcinoma cells.
    Ma Y; Okuda S; Okanishi H; Xu M; Jin C; Endou H; Ohgaki R; Kanai Y
    J Pharmacol Sci; 2024 May; 155(1):14-20. PubMed ID: 38553134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer.
    Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Tanaka S; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
    Br J Cancer; 2008 Feb; 98(4):742-8. PubMed ID: 18253116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.
    Imai H; Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
    Histopathology; 2009 Jun; 54(7):804-13. PubMed ID: 19635099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-A-dependent mTORC1 activation.
    Quan L; Ohgaki R; Hara S; Okuda S; Wei L; Okanishi H; Nagamori S; Endou H; Kanai Y
    J Exp Clin Cancer Res; 2020 Nov; 39(1):266. PubMed ID: 33256804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
    Hwang JH; Voortman J; Giovannetti E; Steinberg SM; Leon LG; Kim YT; Funel N; Park JK; Kim MA; Kang GH; Kim SW; Del Chiaro M; Peters GJ; Giaccone G
    PLoS One; 2010 May; 5(5):e10630. PubMed ID: 20498843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
    Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
    Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant relationship between the LAT1 expression pattern and chemoresistance in ovarian clear cell carcinoma.
    Sato K; Miyamoto M; Takano M; Furuya K; Tsuda H
    Virchows Arch; 2019 Jun; 474(6):701-710. PubMed ID: 30637450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer.
    Toyoda M; Kaira K; Ohshima Y; Ishioka NS; Shino M; Sakakura K; Takayasu Y; Takahashi K; Tominaga H; Oriuchi N; Nagamori S; Kanai Y; Oyama T; Chikamatsu K
    Br J Cancer; 2014 May; 110(10):2506-13. PubMed ID: 24762957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma.
    Riazy M; Kalloger SE; Sheffield BS; Peixoto RD; Li-Chang HH; Scudamore CH; Renouf DJ; Schaeffer DF
    Mod Pathol; 2015 Oct; 28(10):1383-9. PubMed ID: 26226846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma.
    Zhang SR; Li H; Wang WQ; Jin W; Xu JZ; Xu HX; Wu CT; Gao HL; Li S; Li TJ; Zhang WH; Xu SS; Ni QX; Yu XJ; Liu L
    Eur J Surg Oncol; 2019 May; 45(5):769-775. PubMed ID: 30416079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophils infiltrating pancreatic ductal adenocarcinoma indicate higher malignancy and worse prognosis.
    Wang Y; Fang T; Huang L; Wang H; Zhang L; Wang Z; Cui Y
    Biochem Biophys Res Commun; 2018 Jun; 501(1):313-319. PubMed ID: 29738769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.